1. Leukocyte Disorders (White Blood Cell Disorders) –
Pipeline Review, H2 2012
Aarkstore.com announces, The Latest market research report is available in
its vast collection:
Leukocyte Disorders (White Blood Cell Disorders)
– Pipeline Review, H2 2012
You can also request for sample page of above mention reports on
sample@aarkstore.com
Summary
Global Markets Direct’s, Leukocyte Disorders (White Blood Cell Disorders) - Pipeline
Review, H2 2012, provides an overview of the Leukocyte Disorders (White Blood
Cell Disorders) therapeutic pipeline. This report provides information on the
therapeutic development for Leukocyte Disorders (White Blood Cell Disorders),
complete with latest updates, and special features on late-stage and discontinued
projects. It also reviews key players involved in the therapeutic development for
Leukocyte Disorders (White Blood Cell Disorders). Leukocyte Disorders (White
Blood Cell Disorders) - Pipeline Review, H2 2012 is built using data and information
sourced from Global Markets Direct’s proprietary databases, Company/University
websites, SEC filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources, put together by
Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the
availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Leukocyte Disorders (White
Blood Cell Disorders).
- A review of the Leukocyte Disorders (White Blood Cell Disorders) products under
development by companies and universities/research institutes based on
2. Leukocyte Disorders (White Blood Cell Disorders) –
Pipeline Review, H2 2012
information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from
discovery till registration stages.
Table of contents:
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Leukocyte Disorders (White Blood Cell Disorders) Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Leukocyte Disorders (White Blood Cell
Disorders) 8
Leukocyte Disorders (White Blood Cell Disorders) Therapeutics under Development
by Companies 10
Leukocyte Disorders (White Blood Cell Disorders) Therapeutics under Investigation
by Universities/Institutes 13
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Leukocyte Disorders (White Blood Cell Disorders) Therapeutics – Products under
Development by Companies 20
Leukocyte Disorders (White Blood Cell Disorders) Therapeutics – Products under
Investigation by Universities/Institutes 22
Companies Involved in Leukocyte Disorders (White Blood Cell Disorders)
Therapeutics Development 24
Kyowa Hakko Kirin Co., Ltd. 24
GlaxoSmithKline plc 25
Gamida Cell Ltd. 26
Mochida Pharmaceutical Co., Ltd. 27
3. Leukocyte Disorders (White Blood Cell Disorders) –
Pipeline Review, H2 2012
STADA Arzneimittel AG 28
Taiho Pharmaceutical Co., Ltd. 29
Ligand Pharmaceuticals Incorporated 30
Lupin Limited 31
NexMed, Inc. 32
Telik, Inc. 33
Zenotech Laboratories Limited 34
ProMetic Life Sciences Inc. 35
Lipoxen PLC 36
Green Cross Corporation 37
Bolder Biotechnology, Inc. 38
Welichem Biotech Inc. 39
PharmaEssentia Corporation 40
ImmuneRegen BioSciences, Inc. 41
Pfenex Inc. 42
Leukocyte Disorders (White Blood Cell Disorders) – Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Combination Products 44
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 50
Homspera - Drug Profile 50
List of Figures
List of Tables are also include.
For more related Reports Plz follow The link:
Pipeline Review, H2 2012
http://www.aarkstore.com/search/viewresults.asp?search=Pipeline Review, H2
2012&PubId=&pagenum=1